Skip to main content

Repronex Disease Interactions

There are 6 disease interactions with Repronex (menotropins).

Major

Gonadotropins (applies to Repronex) thromboembolism

Major Potential Hazard, Moderate plausibility. Applicable conditions: History - Thrombotic/Thromboembolic Disorder, Thrombotic/Thromboembolic Disorder, Obesity

Thromboembolic events, including venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebrovascular occlusion (stroke), and arterial occlusion resulting in loss of limb, have been reported during administration of gonadotropin therapy, both in association with and independent of the Ovarian Hyperstimulation Syndrome. Therapy with gonadotropins should be administered cautiously to patients with or predisposed to thromboembolism.

References

  1. "Product Information. Humegon (menotropins)." Organon PROD (2001):
  2. "Product Information. Fertinex (urofollitropin)." Serono Laboratories Inc
  3. "Product Information. Bravelle (urofollitropin)." Ferring Pharmaceuticals Inc (2003):
Major

Menotropins (applies to Repronex) uncontrolled non- gonadal endocrinopathies

Major Potential Hazard, High plausibility. Applicable conditions: Adrenal Insufficiency, Hyperadrenocorticism, Adrenal Tumor, Hyperaldosteronism, Thyroid Disease, Panhypopituitarism

The use of menotropins is contraindicated in patients with uncontrolled non- gonadal endocrinopathies such as thyroid, adrenal or pituitary disorders.

References

  1. "Product Information. Humegon (menotropins)." Organon PROD (2001):
Major

Menotropins (applies to Repronex) CNS tumors

Major Potential Hazard, High plausibility. Applicable conditions: Pituitary Tumor, Brain/Intracranial Tumor

The use of menotropins is contraindicated in patients with CNS lesions, such as pituitary gland or hypothalamus tumors. Menotropins possess LH and FSH activity.

References

  1. "Product Information. Humegon (menotropins)." Organon PROD (2001):
Major

Menotropins (applies to Repronex) vaginal bleeding and reproductive organ tumors

Major Potential Hazard, High plausibility. Applicable conditions: Abnormal Uterine Bleeding, Endometrial Dysplasia, Neoplasia -- Estrogen Dependent

The use of menotropins is contraindicated in female patients with abnormal vaginal bleeding of undetermined origin. Patients should be evaluated to ensure neoplastic lesions are not present. The use of menotropins is contraindicated in the presence of sex hormone dependent tumors of the reproductive tract or accessory organs.

References

  1. "Product Information. Humegon (menotropins)." Organon PROD (2001):
Moderate

Gonadotropins (applies to Repronex) pulmonary conditions

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment

Serious pulmonary conditions such as atelectasis, acute respiratory syndrome, and exacerbation of asthma have been reported in women treated with gonadotropins. Caution and monitoring is advised if used in women with pulmonary conditions.

References

  1. "Product Information. Humegon (menotropins)." Organon PROD (2001):
  2. "Product Information. Fertinex (urofollitropin)." Serono Laboratories Inc
  3. "Product Information. Bravelle (urofollitropin)." Ferring Pharmaceuticals Inc (2003):
Moderate

Menotropins (applies to Repronex) renal/hepatic

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Liver Disease

Safety, efficacy and pharmacokinetics of menotropins have not been established in women with renal or hepatic insufficiency. Caution is advised.

References

  1. "Product Information. Humegon (menotropins)." Organon PROD (2001):

Repronex drug interactions

There is 1 drug interaction with Repronex (menotropins).

Repronex alcohol/food interactions

There is 1 alcohol/food interaction with Repronex (menotropins).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer